Groowe Groowe / Newsroom / EVAX
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

EVAX News

Evaxion A/S American Depositary Share

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

globenewswire.com
EVAX

Evaxion raises $7.2 million, extending cash runway to second half of 2027

globenewswire.com
EVAX

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

globenewswire.com
EVAX

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

prnewswire.com
GTBP EVAX RNXT EDAP XNCR GTBP EVAX RNXT EDAP XNCR

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

globenewswire.com
EVAX

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

globenewswire.com
EVAX

Evaxion expands AI-Immunology™ platform with automated vaccine design module

globenewswire.com
EVAX

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

globenewswire.com
EVAX

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

globenewswire.com
EVAX